TCTR20181122001Not yet recruitingPhase 2
Phase II Clinical Trial: Efficacy and Safety of Kaempferia Parviflora in Treatment of Chronic Vertigo Patients
Agricultural Research Development Agency (Public Organization)0 sites72 target enrollmentStarted: November 22, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 72
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Years to 65 Years (—)
- Sex
- All
Inclusion Criteria
- •1. Chronic dizziness patient with symptom persists more than 3 months
- •2. age between 18-65 years old
- •3. Consent to participate in the study and able to follow up until finish
- •4. Never been treated with Kaempferia parviflora or Betahistine in 72 hours prior recruited in to the study
- •5. Able to read and write in Thai
Exclusion Criteria
- •1. Patient with diagnosis of BPPV, Vestibular Migraine, Motion Sickness, Height vertigo, Orthostatic Hypotension, Mental or psychiatric problem, Brain or Vestibular nerve tumor
- •2. Abnormal proprioception test, tremor, hemiplegia paraplegia
- •3. Patient with asymmetrical SNHL or poor SDS or suspected Acoustic Neuroma
- •4 Patient with cardiac arrythmia or arrythmia symptoms
- •5. Patient with active middle ear disease or TM perforate
- •6. patient who received neuro compressive drugs, aspirin, diuretics,aminoglycosides, anti-cancer,anti-epilepsy, antidepressants
- •7. Patient with banormal LFT, GFR less than 60
- •8. Patient who cannot sit and stand
- •9. Patient who unable to follow up
Investigators
Similar Trials
Not yet recruiting
Phase 2
Effect of Kapikacchu basti in management of Kampavata (Parkinsons disease)CTRI/2017/08/009345Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital
Not yet recruiting
Phase 2
Efficacy of Karnapooran and Nasya with Eranda Shigruvadi Taila along with Ghritpana in the Management of Karna Badhirya or Sensorineural Hearing Loss.CTRI/2024/06/068457Ayurvedic college Health Department Government of Bihar
Active, not recruiting
Phase 1
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregional or metastatic breast carcinoma which has progressed on prior trastuzumab-based therapy.A parallel cohort of 15 patients with HER2-positive, PD-L1 negative disease will be enrolled in the phase II study.MedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-ATInternational Breast Cancer Study Group (IBCSG)61
Active, not recruiting
Phase 1
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregionalor metastatic breast carcinoma which has progressed on priortrastuzumab-based therapyMedDRA version: 17.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-ITInternational Breast Cancer Study Group (IBCSG)58
Active, not recruiting
Phase 1
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregional or metastatic breast carcinoma which has progressed on prior trastuzumab-based therapy.A parallel cohort of 15 patients with HER2-positive, PD-L1 negative disease will be enrolled in the phase II study.MedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-BEInternational Breast Cancer Study Group (IBCSG)61